Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Depreciation and Depletion (2016 - 2026)

Oramed Pharmaceuticals filings provide 16 years of Depreciation and Depletion readings, the most recent being $30000.0 for Q4 2025.

  • Quarterly Depreciation and Depletion fell 3.23% to $30000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $121000.0 through Dec 2025, down 37.31% year-over-year, with the annual reading at $121000.0 for FY2025, 37.31% down from the prior year.
  • Depreciation and Depletion hit $30000.0 in Q4 2025 for Oramed Pharmaceuticals, down from $31000.0 in the prior quarter.
  • Across five years, Depreciation and Depletion topped out at $72000.0 in Q3 2021 and bottomed at $11000.0 in Q1 2022.
  • Average Depreciation and Depletion over 5 years is $35400.0, with a median of $30500.0 recorded in 2024.
  • The largest annual shift saw Depreciation and Depletion surged 833.33% in 2021 before it tumbled 46.43% in 2025.
  • Oramed Pharmaceuticals' Depreciation and Depletion stood at $12000.0 in 2021, then soared by 41.67% to $17000.0 in 2022, then soared by 211.76% to $53000.0 in 2023, then plummeted by 41.51% to $31000.0 in 2024, then decreased by 3.23% to $30000.0 in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Depreciation and Depletion are $30000.0 (Q4 2025), $31000.0 (Q3 2025), and $30000.0 (Q2 2025).